1. Home
  2. KNSA vs CCOI Comparison

KNSA vs CCOI Comparison

Compare KNSA & CCOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • CCOI
  • Stock Information
  • Founded
  • KNSA 2015
  • CCOI 1999
  • Country
  • KNSA United Kingdom
  • CCOI United States
  • Employees
  • KNSA N/A
  • CCOI N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • CCOI Telecommunications Equipment
  • Sector
  • KNSA Health Care
  • CCOI Consumer Discretionary
  • Exchange
  • KNSA Nasdaq
  • CCOI Nasdaq
  • Market Cap
  • KNSA 2.6B
  • CCOI 2.2B
  • IPO Year
  • KNSA 2018
  • CCOI N/A
  • Fundamental
  • Price
  • KNSA $38.01
  • CCOI $43.52
  • Analyst Decision
  • KNSA Strong Buy
  • CCOI Buy
  • Analyst Count
  • KNSA 7
  • CCOI 6
  • Target Price
  • KNSA $46.86
  • CCOI $49.17
  • AVG Volume (30 Days)
  • KNSA 454.2K
  • CCOI 1.0M
  • Earning Date
  • KNSA 10-28-2025
  • CCOI 11-06-2025
  • Dividend Yield
  • KNSA N/A
  • CCOI 9.34%
  • EPS Growth
  • KNSA N/A
  • CCOI N/A
  • EPS
  • KNSA 0.47
  • CCOI N/A
  • Revenue
  • KNSA $597,973,000.00
  • CCOI $921,889,000.00
  • Revenue This Year
  • KNSA $53.93
  • CCOI $5.47
  • Revenue Next Year
  • KNSA $25.06
  • CCOI $6.25
  • P/E Ratio
  • KNSA $84.46
  • CCOI N/A
  • Revenue Growth
  • KNSA 55.68
  • CCOI N/A
  • 52 Week Low
  • KNSA $17.82
  • CCOI $29.62
  • 52 Week High
  • KNSA $42.05
  • CCOI $86.76
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 50.20
  • CCOI 55.25
  • Support Level
  • KNSA $35.53
  • CCOI $42.63
  • Resistance Level
  • KNSA $41.28
  • CCOI $44.23
  • Average True Range (ATR)
  • KNSA 1.50
  • CCOI 1.39
  • MACD
  • KNSA -0.14
  • CCOI -0.15
  • Stochastic Oscillator
  • KNSA 43.13
  • CCOI 47.20

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About CCOI Cogent Communications Holdings Inc.

Cogent carries over one-fifth of the world's internet traffic on its network, providing high-capacity services to businesses. Cogent's corporate customers are in high-rise office buildings, where the firm provides two types of connections: dedicated internet access, which connects them to the internet, and virtual private networking, which offers an internal network for employees in different locations. Cogent's corporate customers are exclusively in North America and account for nearly half of the firm's revenue. Cogent's netcentric customers include internet service providers and content providers, to which Cogent provides internet transit. They hand traffic to Cogent in data centers and rely on Cogent to deliver it. About half of netcentric revenue is from outside the US.

Share on Social Networks: